Trial Profile

A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Etoposide (Primary) ; PM-8002 (Primary) ; Atezolizumab
Indications Small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms ROSETTA Lung-01
Sponsors BioNTech

05 May 2025 According to the BioNTech media release, first data from this study will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting taking place from May 30 to June 3, 2025 in Chicago, Illinois.
22 Jan 2025 Planned initiation date changed from 1 Dec 2024 to 1 Jan 2025.
22 Jan 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com